stockrowBristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.02%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Bristol Myers Squibb Company (BMY) Total debt
Bristol Myers Squibb Company's total debt at the end of fiscal 2025 was $45.1B, down 9.14% from $49.6B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $42.9B. Over the past ten years it has ranged from $6.7B (fiscal 2015) to $50.7B (fiscal 2020); the current reading is higher than 73% of that period. Bristol Myers Squibb Company ranks 7th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $45.1B | (9.14%) |
| FY2024 | $49.6B | 24.83% |
| FY2023 | $39.8B | 1.15% |
| FY2022 | $39.3B | (11.75%) |
| FY2021 | $44.6B | (12.08%) |
| FY2020 | $50.7B | 8.44% |
| FY2019 | $46.7B | 535.91% |
| FY2018 | $7.3B | (7.70%) |
| FY2017 | $8.0B | 18.69% |
| FY2016 | $6.7B | 0.28% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $42.9B | (0.56%) |
| Jun 2026 | $43.1B | (3.01%) |
| Mar 2026 | $44.5B | (1.44%) |
| Dec 2025 | $45.1B | (7.90%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| NVS Novartis AG compare | $46.3B |
| BMY Bristol Myers Squibb Company | $42.9B |
| GSK GSK PLC Sponsored ADR compare | $31.9B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
| SNY Sanofi compare | $20.7B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement